Lifeward enters USD 5.58 million senior secured convertible note financing with investors, Oramed agent

Lifeward entered a USD 5.58 million senior secured convertible note financing with Oramed as collateral agent. The initial closing issued notes convertible at $5.40/share with an 8% interest rate and 3-year term. A second tranche is conditional on sales or share price targets. Investors received warrants, and Lifeward amended existing notes to revise redemption terms and ownership limits.

Lifeward entered a securities purchase agreement for senior secured convertible notes with certain investors, with Oramed acting as collateral agent. * Initial closing on July 6, 2026 issued USD 5.58 million of notes, convertible at USD 5.4 per share, with 8% interest and a 3-year term. * A second USD 5.58 million tranche is conditional on a 150% ReWalk unit sales increase or a USD 13.8 share-price test. * Investors also received 5-year warrants, exercisable at USD 5.4 per share, subject to a 19.99% exchange cap without shareholder approval. * Separately, Lifeward amended and restated existing notes and warrants to revise redemption terms, pari passu treatment, and beneficial ownership limits. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-003429), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Lifeward entered a securities purchase agreement for senior secured convertible notes with certain investors, with Oramed acting as collateral agent. * Initial closing on July 6, 2026 issued USD 5.58 million of notes, convertible at USD 5.4 per share, with 8% interest and a 3-year term. * A second USD 5.58 million tranche is conditional on a 150% ReWalk unit sales increase or a USD 13.8 share-price test. * Investors also received 5-year warrants, exercisable at USD 5.4 per share, subject to a 19.99% exchange cap without shareholder approval. * Separately, Lifeward amended and restated existing notes and warrants to revise redemption terms, pari passu treatment, and beneficial ownership limits. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-003429), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here